Meglitinides type 2 diabetes

Meglitinide contains a benzamide group. Meglitinide-related compounds such as nateglinide are non-sulfonylurea oral hypoglycemic drugs used in the treatment of type 2 (non-insulin dependent) diabetes mellitus. 

Insulin Exenatide is not a substitute for insulin in insulin-requiring patients. Do not use exenatide in patients with type 1 diabetes or for the treatment of diabetic ketoacidosis. The concurrent use of exenatide with insulin, thiazolidinediones, D-phenylalanine derivatives, meglitinides, or alpha-glucosidase inhibitors has not been studied. 

Bedtime insulin has been suggested as an adjunct to oral antidiabetic therapy in patients with type 2 diabetes who have not responded to maximal oral therapy. Clinical practice has evolved to include sulfonylureas, meglitinides, D-phenylalanine derivatives, biguanides, thiazolidinediones, or rr.-glucosidase inhibitors given in conjunction with insulin. 

Insulin secretagogues (sulfonylureas, meglitinides, or D -phenylalanine derivatives), Tzds, biguanides, -glucosidase inhibitors, and incretin-based agents are not approved for use in type 1 diabetes. 

There is no indication for combining insulin with insulin secretagogues (sulfonylureas, meglitinides, or D-phenylalanine derivatives) in individuals with type 1 diabetes. Type 1 diabetics with diets very high in starch may benefit from the addition of tt-glucosidase inhibitors, but this is not typically practiced in the USA. 

Trade name Starlix (Novartis) Indications Type 2 diabetes Category Meglitinide Half-life 1.5 hours... 

Indications Non-insulin dependent diabetes type II Category Meglitinide Half-life I hour... 

Oral hypoglycemic (prototype meglitinide) blocks channels in pancreatic B cells, causing depolarization and release of insulin. Used in type 1 diabetes alone, or in combinations rapid onset and short duration. Tox h) oglycemia, increases liver enzymes. 

The meglitinides (e.g. repaglinide) increase endogenous insulin secretion, and so are used in type 2 diabetes. 

Metabolisui The use of meglitinides has been evaluated in China in patients with type 2 diabetes, 433 of whom used nategli-nide and 436 repaglinide, mean age 55 years and BMI 25 kg/m. There was no statistically difference in the rates of adverse events, but the risk of an event was 0.59 times higher in those who took nateglinide the most common adverse event was hypoglycemia [67 ]. 

Meglitinides are another class of drugs used in the management of Type 2 diabetes. Similar to the sulfonylureas, they bind to the pancreatic p-cells, albeit at a different site, and open the calcium channels. This induces insulin secretion. Repaghnide (Prandin , Novo Nordisk) is an example of the class. 

---